Methods and compositions for treating glycogen storage diseases

A composition and genome technology, applied in the direction of gene therapy, botanical equipment and methods, biochemical equipment and methods, etc., can solve the incomplete prevention of hyperlipidemia, hyperuricemia, lactic acidemia and liver fat Accumulated, incurable GSD-Ia and other problems

Pending Publication Date: 2021-09-28
阿尔特拉吉尼克斯制药公司
View PDF13 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] There is currently no cure for GSD-Ia and the current standard of care for patients is dietary supplementation
Dietary strategies often promote normal growth and puberty if followed closely, but dietary therapy does not completely prevent hyperlipidemia, hyperuricemia, lactic acidemia, and hepatic fat accumulation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods and compositions for treating glycogen storage diseases
  • Methods and compositions for treating glycogen storage diseases
  • Methods and compositions for treating glycogen storage diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1-A

[0116] Example 1 - AAV vectors and rAAV produced from vectors

[0117] AAV vector

[0118] An AAV vector containing a G6PC expression cassette surrounded by two AAV2 inverted terminal repeats (ITR, SEQ ID NO: 15) was constructed. The primer sequence "1S" listed in Yiu et al., 2010, Molecular Therapy [Molecular Therapy] 18 (6): 1076-84 and its related G6PC promoter / enhancer (GPE) 5' end KpnI restriction endonuclease site definition. By alignment with the SV40 genome and associated SalI restriction endonuclease sites, the G6PC expression cassette is defined at the 3' end by its SV40 late polyadenylation signal. All G6PC expression cassettes contain GPE, introns, codon-optimized human G6PC gene, and SV40 late poly-A tail, as in Figure 1A shown. Different versions of the G6PC expression cassette were produced, each version containing either wild-type GPE or modified GPE, such as Figure 1B shown. The elements of the G6PC expression cassette are described below.

[0119] T...

Embodiment 2

[0128] Example 2-Alu element deletion improves rAAV production

[0129] AAV vectors containing wild-type GPE or modified GPE were used to transfect HEK293 cells with the Rep / Cap plasmids and helper plasmids described above.

[0130] The Alu element was deleted (in DTC175, DTC177 and DTC178 vectors) or the Alu element was reversed in orientation (in DTC176 and DTC179 vectors) in the modified GPE. The DTC175 viral vector contains a G6PC expression cassette containing GPE in which the Alu-1 and Alu-2 sequences have been deleted, and the DTC176 viral vector contains a G6PC expression cassette containing a GPE with all three Alu elements Both exist, but the orientation of the Alu-1 and Alu-2 sequences is reversed, and the DTC177 viral vector contains a G6PC expression cassette comprising GPE in which the Alu-1, Alu-2 and Alu-3 sequences are deleted, The DTC178 viral vector comprises a G6PC expression cassette comprising GPE in which the Alu-3 sequence has been deleted, and the DTC...

Embodiment 3-A

[0134] Example 3 - Alu element deletion improves rAAV packaging

[0135] To assess whether deletion of one or more Alu elements affected rAAV packaging, rAAV produced as described in Example 2 were harvested and extracted from each rAAV (produced from control viral vectors DTC161, DTC175, DTC176, DTC177, DTC178, or DTC179). Total DNA was isolated. about 7.12x10 10 Total amounts of each rAAV GC were subjected to agarose gel electrophoresis followed by SYBRGold staining. The control viral vector used in this experiment was AAV8-LSP-hFIXco3-WPRE-pA (produced at Virovek, custom purified, 150282 cat / lot 061015), which provides the known DNA size on the gel migration, and confirmed that the experimental approach was able to disrupt the integrity of the AAV capsid and release the packaged DNA.

[0136] Such as Figure 7 As shown, the full-length viral DNA is between 3.8kb-5kb. "*" indicates the complete genome of full-length DNA isolated from a control viral vector after capsid ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

This invention provides a variety of novel adeno-associated virus (AAV) vectors for gene therapy applications in the treatment of glycogen storage disease type la (GSD-Ia). Disclosed herein are a number of recombinant nucleic acid molecules, vectors and recombinant AAV that incorporate a modified G6PC promoter / enhancer sequence. Utilization of the modified G6PC promoter / enhancer sequence results in enhanced AAV yield and quality when expressed from various host cell platforms. Also provided herein are compositions comprising the novel AAV of the invention and methods of treating GSD-Ia using the same.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62 / 781,380, filed December 18, 2018, the disclosure of which is hereby incorporated by reference in its entirety for all purposes. [0003] sequence listing [0004] This application contains a Sequence Listing, which has been filed electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on December 16, 2019, is named DIM-010WO_SL_ST25.txt and is 42,290 bytes in size. technical field [0005] The present application relates generally to viral vectors for use in the treatment of glycogen storage diseases, such as glycogen storage disease type Ia, and more particularly to adeno-associated viral vectors. Background technique [0006] Glycogen storage disease type Ia (also known as GSD-Ia or von Gierke disease) is an inherited disorder caused by the accumulation of glycog...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/55C12N15/864C12N9/16C12N5/10A61K38/46A61K48/00
CPCC12N9/16C12N15/8645C12N15/86A61K48/00C12Y301/03009C12N2750/14143A61K38/00C12N15/11C12N2320/35C12N2830/34C12N2830/42C12N2830/50
Inventor 克里斯托弗·蒂珀凯利·里德·克拉克塞缪尔·沃兹沃思
Owner 阿尔特拉吉尼克斯制药公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap